Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial
Patrick Kwan, Martin J Brodie, Reetta Kalviainen, Lorraine Yurkewicz, Jerry Weaver, Lloyd E Knapp
Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2011
Pfizer Inc.This Article concerns a use of pregabalin that is not approved by the FDA. PK has served on a speakers' bureau for Eisai, serves on a scientific advisory board for Pfizer Inc, and receives research grants from Eisai, Johnson & Johnson, Pfizer Inc, and UCB Pharma. MJB serves on scientific advisory boards for Pfizer Inc, UCB Pharma, Eisai, Johnson & Johnson, GlaxoSrnithKline, Novartis, Valeant Pharmaceuticals International, Sierra Neuropharmaceuticals, Neuronex, and Medtronic; has received funding for travel from UCB Pharma; serves as a consultant for Sisal; serves on speakers' bureaus for UCB Pharma, GlaxoSmithKline, and Eisai; and has received research support from Pfizer Inc, UCB Pharma, and Eisai. RK has served on scientific advisory boards for Pfizer Inc, UCB Pharma, and GlaxoSmithKline; has received funding for travel from UCB Pharma and Eisai; has served on speakers' bureaus for UCB Pharma, Eisai, and Orion; and has received research support from UCB Pharma. LY, JW, and LK are employees of Pfizer Inc.Editorial support was provided by Patricia McChesney of UBC Scientific Solutions and was funded by Pfizer Inc.